FF2039
FF2039 is a pan-HDAC PROTAC degrader that binds to DCAF11, acting on HDAC6, HDAC1, HDAC2 and HDAC4. FF2039 recruits the DCAF11 E3 ligase and mediates the polyubiquitination and degradation of HDACs via the ubiquitin-proteasome system. FF2039 induces cell cycle arrest, apoptosis, cytotoxicity and antiproliferative activity in cancer cells, and reduces the clonogenic capacity of cancer cells. FF2039 is applicable to research related to multiple myeloma, triple-negative breast cancer and glioblastoma.
(Pink: HDAC1 and HDAC2 and HDAC4 and HDAC6 ligand (HY-168864); Blue: Ligands for E3 Ligase ligand (HY-W957284); Black: linker (HY-W881439)).
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Formule: C43H56Cl3N5O6
- Masse moléculaire:845.29
-
Stockage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Voir tous les produits spécifiques à Isoform PROTACs
More
Activité biologique
Description
IC50 & Target
[1]|
HDAC1 1.03 μM (IC50) |
HDAC2 2.15 μM (IC50) |
HDAC4 12.4 μM (IC50) |
HDAC6 0.053 μM (IC50) |
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| MDA-MB-231 | EC50 |
28 μM
|
Antiproliferative activity against triple negative breast cancer MDA-MB-231 cells assessed as reduction in cell viability incubated for 72 hrs by cell viability assay.
Antiproliferative activity against triple negative breast cancer MDA-MB-231 cells assessed as reduction in cell viability incubated for 72 hrs by cell viability assay.
|
39973224 |
| U-87MG ATCC | EC50 |
30 μM
|
Antiproliferative activity against glioblastoma U-87MG cells assessed as reduction in cell viability incubated for 72 hrs by cell viability assay.
Antiproliferative activity against glioblastoma U-87MG cells assessed as reduction in cell viability incubated for 72 hrs by cell viability assay.
|
39973224 |
In Vitro
FF2039 (compound 1J) inhibits purified HDAC1, HDAC2, HDAC4, and HDAC6 proteins, with IC50 values of 1.03 μM, 2.15 μM, 12.4 μM, and 0.053 μM, respectively[1].
FF2039 (10 μM; 24 h) reduces HDAC1 levels by 71% and induces significant degradation of HDAC6 in MM.1S cells. It binds HDAC6 and class I HDACs in MM.1S cells, inducing hyperacetylation of α-tubulin and histone H3. It also induces significant degradation of HDAC1 and HDAC6 in U-87MG cells, with degradation efficacy weaker than that observed in MM.1S cells[1].
FF2039 (10 μM; 24 h) acts as a pan-HDAC degrader in MM.1S cells, achieving a maximum degradation rate of 90% for HDAC1 and 71%-76% for HDAC2, HDAC4 and HDAC6, with significant degradation effects observed as early as 6 h[1].
FF2039 (72 h) inhibits the proliferation of MM.1S cells with an EC50 of 2.8 μM; it also inhibits the proliferation of MDA-MB-231 and U-87MG cells, with an EC50 of 28 μM for the former and 30 μM for the latter[1].
FF2039 (10 μM; 48 h) induces cell cycle arrest and significant apoptosis in MM.1S cells, and significantly reduces the clonogenic capacity of MDA-MB-231 cells[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:multiple myeloma MM.1S cells
-
Concentration:10 μM
-
Incubation Time:24 h
-
Result:Reduced HDAC1 protein levels by 71%.
Achieved significant reduction of HDAC6 protein levels in MM.1S cells.\nInduced hyperacetylation of α-tubulin (a marker of HDAC6 inhibition) in MM.1S cells.
Induced hyperacetylation of histone H3 (a marker of class I HDAC inhibition) in MM.1S cells, with histone H3 hyperacetylation more pronounced than seen with comparator compounds.
-
Cell Line:glioblastoma U-87MG cells
-
Concentration:10 μM
-
Incubation Time:24 h
-
Result:Achieved significant degradation of HDAC1 and HDAC6 in U-87MG cells, though degradation was weaker than observed in MM.1S cells.
-
Cell Line:multiple myeloma MM.1S cells
-
Concentration:10 μM
-
Incubation Time:48 h
-
Result:Induced an increase in the sub G1 phase and a decrease in the S phase of the cell cycle, indicating cell cycle arrest.
Induced significant levels of early and late apoptosis, comparable to HDAC inhibitors.
-
Cell Line:multiple myeloma MM.1S cells
-
Concentration:10 μM
-
Incubation Time:48 h
-
Result:Induced significant apoptosis in MM.1S cells.
-
Cell Line:MDA-MB-231 cells
-
Concentration:10 μM
-
Incubation Time:48 h
-
Result:Reduced clonogenic growth of MDA-MB-231 cells, outperforming HDAC inhibitors Ricolinostat (HY-16026) and Vorinostat (HY-10221).
Chemical Information
-
Masse moléculaire 845.29
-
Formule C43H56Cl3N5O6
-
SMILES
O=C(NCCCCCCC(NO)=O)C1=CC=C(NC(CCCCCCCCCCCN(C(C2=CC=C(Cl)C(Cl)=C2)C(NCC3=CC=CC=C3)=O)C(CCl)=O)=O)C=C1
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocole
-
Apoptosis
Apoptosis, also called programmed cell death, is generally characterized by distinct morphological characteristics.
-
TUNEL staining for apoptotic DNA fragmentation
TUNEL staining detects DNA strand breaks by using terminal deoxynucleotidyl transferase to add labeled nucleotides to exposed 3′-OH DNA termini, generating either microscopic staining in fixed cells or tissue sections, or fluorescence/cytometric signal in cell suspensions. TUNEL positivity reflects DNA fragmentation but should not be interpreted alone as definitive apoptosis, because TUNEL can also label necrotic, autolytic, mechanically damaged, or DNA-repair-associated DNA breaks.
-
Flow cytometric DNA-content cell-cycle staining
Flow cytometric DNA-content cell-cycle staining measures the fluorescence intensity of DNA-bound fluorochromes in single cells or nuclei to estimate DNA content distributions, allowing assignment of populations to G0/G1, S, and G2/M phases by DNA histogram deconvolution. Propidium iodide (PI) intercalates into DNA, and PI fluorescence is proportional to cellular DNA content when staining is performed under conditions that make DNA accessible and minimize non-DNA signal. Cells with G2/M DNA content are expected to show approximately twice the fluorescence intensity of G0/G1 cells, while S-phase cells occupy intermediate fluorescence values. PI-based DNA-content analysis can also detect cells with fractional DNA content, often reported as sub-G1, when DNA fragmentation and extraction during staining reduce retained DNA signal in apoptotic cells. DAPI is an alternative DNA fluorochrome for univariate DNA-content analysis, while bivariate approaches combining DNA content with proliferation
-
Cell Cytotoxicity Assay
Cytotoxicity assays are usually based on the assessment of cell membrane damage, which can also be indirectly detected by measuring cell viability. Detection methods include MTT assay, CKK-8 assay, LDH assay and ATP assay, etc.
-
Mammalian live/dead viability and cytotoxicity staining
Live/dead viability and cytotoxicity staining assays are based on the simultaneous detection of intracellular esterase activity in metabolically active (viable) cells and membrane integrity loss in non-viable cells. In commonly used dual-staining approaches, membrane-permeant fluorogenic substrates are converted by intracellular esterases into fluorescent products in live cells, while impermeant DNA-binding dyes selectively enter cells with compromised plasma membranes and label nucleic acids in dead or dying cells, enabling discrimination between viable and non-viable populations by fluorescence microscopy or flow cytometry.
-
Annexin V plus membrane-impermeant dye apoptosis staining
Annexin V-based apoptosis assays rely on the detection of phosphatidylserine (PS) externalization from the inner leaflet of the plasma membrane to the outer leaflet, an early biochemical hallmark of apoptosis. Fluorescently labeled Annexin V binds PS in a calcium-dependent manner, enabling identification of early apoptotic cells by flow cytometry or fluorescence microscopy. When combined with a membrane-impermeant DNA-binding dye (e. g. , propidium iodide), this approach allows discrimination between viable (Annexin V−/dye−), early apoptotic (Annexin V+/dye−), and late apoptotic or necrotic (Annexin V+/dye+) cell populations by assessing membrane integrity and PS exposure.
-
BrdU Incorporation Assay
Bromodeoxyuridine (BrdU) incorporation assay is based on the principle that BrdU, a thymidine analog, is incorporated into newly synthesized DNA during the S phase of the cell cycle, thereby serving as a marker of DNA replication and cellular proliferation. Incorporated BrdU can be detected using anti-BrdU antibodies following DNA denaturation, enabling visualization or quantification of proliferating cells through immunochemical detection methods such as immunofluorescence or immunohistochemistry.
-
Apoptosis Solutions
Apoptosis is a regulated, generally non-lytic cell-death pathway that removes unwanted, damaged, infected, or abnormal cells through coordinated morphological changes, caspase activation, DNA fragmentation, and membrane remodeling. The intrinsic apoptosis pathway is controlled mainly by mitochondrial outer membrane permeabilization, BCL-2 family proteins, cytochrome c release, apoptosome formation, caspase-9 activation, and downstream executioner caspase-3/7 activation. The extrinsic apoptosis pathway is initiated by death receptors such as Fas, TNFR, and TRAIL receptors, which recruit adaptor proteins and activate caspase-8 before engaging executioner caspases or mitochondrial amplification through BID cleavage. Apoptosis is linked to many phenotypes, including cancer cell killing, tissue homeostasis, immune regulation, neurodegeneration, infection response, and treatment-induced cytotoxicity; unresolved questions include how apoptosis interacts with necroptosis, pyroptosis, ferroptos
-
Protocol for Cell Cycle
Cell-cycle analysis by flow cytometry measures DNA content in single cells to estimate the fraction of cells in G0/G1, S, and G2/M phases. Propidium iodide intercalates into DNA, and after RNA removal with RNase, fluorescence intensity reflects cellular DNA content: 2N cells are assigned to G0/G1, cells between 2N and 4N to S phase, and 4N cells to G2/M. DNA-content analysis alone cannot reliably separate G0 from G1 or G2 from M. Ki-67 can distinguish quiescent G0 cells from cycling cells, EdU or BrdU incorporation marks active DNA synthesis in S phase, and phospho-histone H3 staining identifies mitotic cells within the 4N population.
-
Breast Cancer Modeling
Breast cancer is a heterogeneous cancer, and it has been distinguished into four subtypes: luminal A, luminal B, HER2-positive and basal-like. Molecular mutations, epigenetic alterations, hormone exposure and immune microenvironment are related to the progression of breast cancer.
-
Cell Viability Determination by MTT Colorimetric Assay
The following protocol uses the MTT colorimetric assay as a classic literature-established method for assessing cell viability/metabolic activity in cultured mammalian cells. MTT[3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] is reduced by metabolically active cells to a colored formazan product; the amount of formazan is quantified spectrophotometrically and provides an indirect measure of metabolically active viable cells. Importantly, MTT reduction reflects cellular oxidoreductase/metabolic activity rather than an absolute direct count of living cells, so changes in cellular metabolism can alter the signal independently of cell number.
Pureté et documentation
Références
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)